SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert L. Ray who wrote (82)9/21/1998 2:50:00 PM
From: H. Bradley Toland, Jr.  Read Replies (1) of 127
 
A second Renagel follow up. My conclusion for the dialysis market is comparable to your $200 - $300 million a year. I get to $500 million because the number for people with impaired kidney function, but not on dialysis, in the U.S. alone is greater than 800,000. Many of these are good candidates to use Renagel even though they may never be on dialysis. Geltex has begun a study for predialysis patients but once a product is approved, Nephrologists may use it as they see fit. My expectation (or hope!) is that Renagel will enjoy a quick sales ramp-up for the 1/3 of dialysis patients who are hypercalcemic and then act like the energizer bunny--just steady growth quarter after quarter.
Doug Rogers
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News